The Dynamics of Neurofilament Light Chain in Spinal Muscular Atrophy - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Exploring the Role of Neurofilament Light Chain in Spinal Muscular Atrophy

  • By

  • Arlene D'Silva

  • Karen Herbert

  • Lakshmi Balaji

  • Jia Mei He

  • Tejaswi Kandula

  • Hugo A. Sampaio

  • Hooi-Ling Teoh

  • Esther Tantsis

  • Jihee Sohn

  • Nancy Briggs

  • Nickson Ning

  • Matthew C. Kiernan

  • Didu S. Kariyawasam

  • Michelle A. Farrar

  • July 1, 2026

Share

Clinical Scorecard: Exploring the Role of Neurofilament Light Chain in Spinal Muscular Atrophy

At a Glance

CategoryDetail
ConditionSpinal Muscular Atrophy (SMA)
Key MechanismsNeurofilament light chain (NfL) levels reflect disease activity and correlate with disease severity.
Target PopulationIndividuals with biallelic deletions of exon 7 on survival motor neuron 1 (SMN1), including neonates and children.
Care SettingTertiary neuromuscular service

Key Highlights

  • NfL levels are significantly higher in children with SMA compared to typically developing peers.
  • NfL is considered a surrogate endpoint in clinical trials and for clinical care.
  • There is a need for further investigation of NfL in neonates identified through newborn screening.
  • High NfL levels are observed in individuals with a 2 SMN2 copy genotype.
  • The study evaluates pretreatment NfL levels against disease characteristics and longitudinal changes.

Guideline-Based Recommendations

Diagnosis

  • NfL levels can aid in the diagnosis and monitoring of SMA.

Management

  • Consideration of NfL as a biomarker for treatment response and disease progression.

Monitoring & Follow-up

  • Longitudinal tracking of NfL levels is crucial for assessing disease activity.

Risks

  • Variability in NfL levels among individuals with different SMN2 copy numbers may complicate prognostication.

Patient & Prescribing Data

Individuals with SMA, particularly those identified through newborn screening.

NfL suppression is associated with SMN protein repletion from disease-modifying treatments.

Clinical Best Practices

  • Utilize NfL levels for prognostication and treatment monitoring in SMA.
  • Incorporate NfL analysis in clinical trials for SMA therapies.

Related Resources & Content

Original Source(s)

The Dynamics of Neurofilament Light Chain in Spinal Muscular Atrophy

  • by Arlene D'Silva, Karen Herbert, Lakshmi Balaji, Jia Mei He, Tejaswi Kandula, Hugo A. Sampaio, Hooi-Ling Teoh, Esther Tantsis, Jihee Sohn, Nancy Briggs, Nickson Ning, Matthew C. Kiernan, Didu S. Kariyawasam, Michelle A. Farrar

  • July 1, 2026

Related Content

Arteriovenous Malformations in Children: A Pediatric Neurosurgeons Perspective

This Neuroscience Grand Rounds session, led by Muhammad Osama, MD, provides a pediatric neurosurgeon’s perspective on arteriovenous malformations (AVMs) in children, rare but high-risk vascular lesions that can lead to seizures, neurological deficits, or life-threatening hemorrhage.

  • June 19, 2026

  • 1 min
Early Neurodevelopmental Outcomes in Pediatric Congenital Heart Disease

In a multicenter registry study, genetic diagnoses were associated with substantially lower cognitive, language, and motor scores; while birth weight, surgical timing, hospitalization burden, and caregiver education were also associated with outcomes.

Armed Conflict and Penetrating Traumatic Brain Injury in Children in the Gaza Strip